Journal of Urology Supplement Focuses on Focal Therapy as a Prostate Cancer Treatment

IRVINE, Calif., Jan. 8 /PRNewswire-FirstCall/ -- Endocare, Inc. (Nasdaq: ENDO), an innovative medical device company focused on the development of minimally invasive technologies used by urologists and interventional radiologists for tissue and tumor ablation, announced today that a Gold Supplement to the December edition of the journal Urology is focused on a series of 12 peer-reviewed studies on the use of focal therapy in the treatment of prostate cancer. The studies were conducted by a group of leading urologists and radiologists led by David Bostwick, M.D., a pathologist specializing in urology, and Gary Onik, M.D., an interventional radiologist, both of whom served as co-editors of the supplement. This is the first published scientific compendium dedicated solely to focal prostate cancer treatment. One of the leading focal treatment methods is cryoablation, or the minimally invasive freezing of the cancerous tumors to destroy them.

read the article >> http://www.streetinsider.com/Press+Releases/Journal+of+Urology+Supplement+Focuses+on+Focal+Therapy+as+a+Prostate+Cancer+Treatment/3247719.html